Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanotech bill

This article was originally published in The Gray Sheet

Executive Summary

The Nanotechnology Safety Act of 2010, introduced Jan. 21 by Sens. Mark Pryor, D-Ariz., and Benjamin Cardin, D-Md., would establish a program within FDA "to assess the health and safety implications of nanotechnology in everyday products and develop best practices for companies who employ nanotechnology," according to Pryor. The program would be carried out at FDA's National Center for Toxicology Research in Jefferson, Ariz., and at FDA headquarters in White Oak, Md. Nanotechnology "has hundreds of promising applications," Pryor said. "As these products are developed and used, we must understand any potential risks to human health, safety or the environment.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT028444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel